Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a Ph 1 ready Molecular Glue for GIST February 25, 2026
BostonGene Announces Strategic Collaboration with Daiichi Sankyo to Accelerate Drug Development Through AI-Driven Multimodal Analytics February 25, 2026
FDA accepts NDA for giredestrant in ESR1-mutated, ER+ advanced breast cancer; PDUFA Dec 2026 February 25, 2026
FDA approves monthly RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) in 1L EGFR+ NSCLC February 25, 2026
Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors February 25, 2026
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200M Concurrent Private Placement February 25, 2026
SURGE Therapeutics Raises $32M Series B Financing to Advance Intraoperative Immunotherapy to Improve Cancer Patient Survival Outcomes Post-Surgery February 25, 2026
Sift Biosciences Announces Oversubscribed $3.7M Pre-seed Financing to Advance Next-gen T-cell Immunotherapy Platform February 25, 2026
Candel Therapeutics’ $100M Royalty Funding Agreement with RTW to Support Aglatimagene Besadenovec (CAN-2409) Launch in Localized Prostate Cancer Announced February 25, 2026
First Patient Dosed in Ph 2 Study of Givastomig-Nivolumab combo in Patients with 1L Metastatic HER2-neg Gastric Cancer February 25, 2026
Planned Milestones in Ongoing Ph 2 DURIPANC Trial of Ampligen and Durvalumab in the Treatment of Metastatic Pancreatic Cancer Announced February 25, 2026
Zenocutuzumab Treatment Beyond Progression Demonstrates Continued Benefit in Patients with NRG1+ NSCLC in New Results from the eNRGy Trial February 25, 2026
First Interim Analysis in the Global Phase 3 FIERCE-HN Study of ficlatuzumab Completed February 25, 2026
MHRA and REC approved CTA for Ph 1 ZIMA-101 trial of ZI-MA4-1 in patients with advanced solid cancers February 25, 2026
FDA Clears IND Application for CS2009 (PD-1/VEGF/CTLA-4) to Advance into Ph 2 Clinical Trial February 25, 2026
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer February 25, 2026
IND filed with FDA for Ph 2 study of TBS-2025 for the treatment of R/R mutNPM1 AML in combination with a menin inhibitor February 25, 2026
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2+ve Early Breast Cancer February 25, 2026
DATROWAY Supplemental NDA Submitted in Japan for Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy February 25, 2026
Adoption of Amended Protocol for Ph 3 VERSATILE-003 Trial Incorporating PFS as Primary Endpoint for Interim Analysis and Potential Accelerated Approval Announced February 25, 2026
